Form 4: CytomX Therapeutics Director Alan Ashworth Acquires Stock Options

Alan Ashworth, a director of CytomX Therapeutics, acquired stock options for 38,000 shares on May 15, 2024.

Summary

• On May 15, 2024, Alan Ashworth, a director of CytomX Therapeutics, acquired stock options for 38,000 shares of common stock at an exercise price of $1.96.
• The options vest on the earlier of the first anniversary of the grant date or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is an option grant, which is part of standard compensation.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon Alan Ashworth's continuous service as a director, suggesting an expectation of his continued involvement with the company.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment, as it may signal confidence in the company's future.

Key Dates